Under a novel nomenclature agreed upon by three prominent global liver organizations, a prevalent liver ailment is set to undergo a significant rebranding. As of June 15, 2023, the terms “non-alcoholic fatty liver disease” and “non-alcoholic steatohepatitis” will be superseded by “metabolic dysfunction–associated steatotic liver disease” (MASLD) and “metabolic dysfunction associated steatohepatitis” (MASH).
The rationale behind this transformation stems from the limitations of the old terminology, which defined the disease based on what it was not, leading to potential confusion and stigma. The new terms, by contrast, focus on the physiological processes involved: fat accumulation in the liver related to metabolic dysfunction. This consensus, achieved through a modified Delphi process, was reached by the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Latin American Association for the Study of Liver.
This cross-continental accord lends credibility to the new nomenclature, positioning it as a coordinated initiative from leading professional bodies shaping liver care standards. The revised classification system doesn’t merely rename existing categories; it introduces a new category: “metabolic and alcohol associated liver disease,” or metALD.
This category addresses cases where both metabolic factors and alcohol consumption contribute to liver disease, a scenario that the previous system often failed to account for. The old system often left patients in a diagnostic grey area, particularly those with obesity who also consumed moderate amounts of alcohol. MetALD acknowledges this overlap and offers a label for it.
Fatty liver disease, also known as hepatic steatosis or steatotic liver disease, remains a concerning public health issue. The condition, characterized by excessive fat deposits in liver cells, often presents without symptoms or mild ones, such as fatigue or an upper right abdominal discomfort.
However, if left untreated, it can advance to cirrhosis, liver cancer, and esophageal varices, which are swollen veins in the esophagus prone to rupture and bleeding. The disease can be broadly categorized into two main subtypes: MASLD, driven by metabolic factors such as obesity, insulin resistance, and high blood lipids; and alcoholic liver disease, caused by chronic heavy drinking. MetALD occupies the space between these two categories, offering a more comprehensive view of liver disease etiology.
This updated framework provides healthcare professionals with a clearer understanding of liver pathology and the underlying mechanisms. The renaming initiative reflects a broader trend in medicine, with a growing preference for inclusive terminology that describes diseases based on their characteristics rather than what they are not.
The shift in nomenclature also impacts research, as clinical trials for fatty liver drugs will now utilize MASH instead of NASH. This change influences trial design, patient recruitment, and interpretation of results. For patients, the immediate impact is minimal; the diagnosis and treatment remain the same.
However, the new language around the disease may alter perceptions, shaping how doctors think, how patients comprehend their condition, and how the public perceives the magnitude of the problem. Fatty liver disease affects millions worldwide.
By providing a clearer name, this renaming initiative represents a step towards improved understanding and management of this significant health concern.
Related Stories
Fatty liver disease: New classification and understanding as of June 2023 #LiverGroupsRename #FattyLiverDisease #MASLDMASH #Health #News
